mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats

Biochemical Pharmacology

Volumn 79, Issue 1, 2010, Pages 67-76

  Nakagawa, Shunsaku ^a   Masuda, Satohiro ^a   Nishihara, Kumiko ^a   Inui, Ken ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Albuminuria; Chronic kidney disease; Drug transporter; Mammalian target of rapamycin; Proximal tubule injury

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; CARRIER PROTEIN; EVEROLIMUS; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN P; KIDNEY INJURY MOLECULE 1; MAMMALIAN TARGET OF RAPAMYCIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PROTEIN KINASE B; PROTEIN S6; S6 KINASE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM PROTON EXCHANGE PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GLOMERULUS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE DISORDER; KIDNEY TUBULE EPITHELIUM; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENAL PROTECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; DISEASE PROGRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; MALE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; RATS, WISTAR; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 70350196384     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.07.015     Document Type: Article

References (48)

1. Taal M.W., and Brenner B.M. Adaptation to nephron loss. In: Brenner B.M. (Ed). The kidney (2008), WB Saunders 783-819
2. Remuzzi G., and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339 (1998) 1448-1456
3. Takeuchi A., Masuda S., Saito H., Doi T., and Inui K. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int 60 (2001) 1058-1068
4. Ji L., Masuda S., Saito H., and Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 62 (2002) 514-524
5. Horiba N., Masuda S., Takeuchi A., Saito H., Okuda M., and Inui K. Gene expression variance based on random sequencing in rat remnant kidney. Kidney Int 66 (2004) 29-45
6. Nishihara K., Masuda S., Ji L., Katsura T., and Inui K. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochem Pharmacol 73 (2007) 1482-1490
7. Kwon T.H., Frokiaer J., Fernandez-Llama P., Maunsbach A.B., Knepper M.A., and Nielsen S. Altered expression of Na transporters NHE-3, NaPi-II, Na-K-ATPase, BSC-1, and TSC in CRF rat kidneys. Am J Physiol 277 (1999) F257-F270
8. Takahashi K., Masuda S., Nakamura N., Saito H., Futami T., Doi T., et al. Upregulation of H(+)-peptide cotransporter PEPT2 in rat remnant kidney. Am J Physiol Renal Physiol 281 (2001) F1109-F1116
9. Sun H., Frassetto L., and Benet L.Z. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109 (2006) 1-11
10. Matsuzaki T., Watanabe H., Yoshitome K., Morisaki T., Hamada A., Nonoguchi H., et al. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure. Kidney Int 71 (2007) 539-547
11. Fingar D.C., and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 (2004) 3151-3171
12. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
13. Inoki K., Corradetti M.N., and Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37 (2005) 19-24
14. Stallone G., Infante B., Schena A., Battaglia M., Ditonno P., Loverre A., et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 16 (2005) 3755-3762
15. Pontrelli P., Rossini M., Infante B., Stallone G., Schena A., Loverre A., et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85 (2008) 125-134
16. Shillingford J.M., Murcia N.S., Larson C.H., Low S.H., Hedgepeth R., Brown N., et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103 (2006) 5466-5471
17. Nagai K., Matsubara T., Mima A., Sumi E., Kanamori H., Iehara N., et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 68 (2005) 552-561
18. Lloberas N., Cruzado J.M., Franquesa M., Herrero-Fresneda I., Torras J., Alperovich G., et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17 (2006) 1395-1404
19. Diekmann F., Rovira J., Carreras J., Arellano E.M., Banon-Maneus E., Ramirez-Bajo M.J., et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 18 (2007) 2653-2660
20. Vogelbacher R., Wittmann S., Braun A., Daniel C., and Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84 (2007) 1492-1499
21. Yokomasu A., Yano I., Sato E., Masuda S., Katsura T., and Inui K. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. Drug Metab Pharmacokinet 23 (2008) 469-475
22. Masuda S., Saito H., Nonoguchi H., and Tomita K. Inui K. mRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. FEBS Lett 407 (1997) 127-131
23. Ichimura T., Bonventre J.V., Bailly V., Wei H., Hession C.A., Cate R.L., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273 (1998) 4135-4142
24. Ogihara H., Saito H., Shin B.C., Terado T., Takenoshita S., Nagamachi Y., et al. Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 220 (1996) 848-852
25. Takahashi K., Nakamura N., Terada T., Okano T., Futami T., Saito H., et al. Interaction of beta-lactam antibiotics with H+/peptide cotransporters in rat renal brush-border membranes. J Pharmacol Exp Ther 286 (1998) 1037-1042
26. Urakami Y., Okuda M., Masuda S., Saito H., and Inui K. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 287 (1998) 800-805
27. Urakami Y., Nakamura N., Takahashi K., Okuda M., Saito H., Hashimoto Y., et al. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 461 (1999) 339-342
28. Hashida T., Masuda S., Uemoto S., Saito H., Tanaka K., and Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 69 (2001) 308-316
29. Tao Y., Kim J., Schrier R.W., and Edelstein C.L. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16 (2005) 46-51
30. Chen J.K., Chen J., Neilson E.G., and Harris R.C. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16 (2005) 1384-1391
31. Andreucci M., Fuiano G., Presta P., Esposito P., Faga T., Bisesti V., et al. Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells. Biochem Pharmacol 72 (2006) 1334-1342
32. Mariappan M.M., Shetty M., Sataranatarajan K., Choudhury G.G., and Kasinath B.S. Glycogen synthase kinase 3beta is a novel regulator of high glucose- and high insulin-induced extracellular matrix protein synthesis in renal proximal tubular epithelial cells. J Biol Chem 283 (2008) 30566-30575
33. Birn H., and Christensen E.I. Renal albumin absorption in physiology and pathology. Kidney Int 69 (2006) 440-449
34. Russo L.M., Sandoval R.M., Campos S.B., Molitoris B.A., Comper W.D., and Brown D. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 20 (2009) 489-494
35. Letavernier E., Bruneval P., Vandermeersch S., Perez J., Mandet C., Belair M.F., et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24 (2009) 630-638
36. Boron W.F. Acid-base transport by the renal proximal tubule. J Am Soc Nephrol 17 (2006) 2368-2382
37. Inui K., Masuda S., Saito H., and Cellular. molecular aspects of drug transport in the kidney. Kidney Int 58 (2000) 944-958
38. Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M., et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13 (2002) 866-874
39. Urakami Y., Akazawa M., Saito H., and Okuda M. Inui K. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13 (2002) 1703-1710
40. Masuda S., Terada T., Yonezawa A., Tanihara Y., Kishimoto K., Katsura T., et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 17 (2006) 2127-2135
41. van Timmeren M.M., Bakker S.J., Vaidya V.S., Bailly V., Schuurs T.A., Damman J., et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol 291 (2006) F456-F464
42. Ichimura T., Asseldonk E.J., Humphreys B.D., Gunaratnam L., Duffield J.S., and Bonventre J.V. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 118 (2008) 1657-1668
43. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112 (2003) 1776-1784
44. Kliem V., Johnson R.J., Alpers C.E., Yoshimura A., Couser W.G., Koch K.M., et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49 (1996) 666-678
45. Ng Y.Y., Huang T.P., Yang W.C., Chen Z.P., Yang A.H., Mu W., et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 54 (1998) 864-876
46. Lamouille S., and Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178 (2007) 437-451
47. Wu M.J., Wen M.C., Chiu Y.T., Chiou Y.Y., Shu K.H., and Tang M.J. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 69 (2006) 2029-2036
48. Sabbatini M., Sansone G., Uccello F., De Nicola L., Nappi F., and Andreucci V.E. Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. Transplantation 69 (2000) 1946-1990